Sandoz Group AG (Sandoz Group AG) Construction In Progress : $432 Mil (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG Construction In Progress?

Sandoz Group AG's quarterly construction in progress increased from . 20 ($0 Mil) to Dec. 2022 ($381 Mil) and increased from Dec. 2022 ($381 Mil) to Dec. 2023 ($432 Mil).

Sandoz Group AG's annual construction in progress increased from . 20 ($0 Mil) to Dec. 2022 ($381 Mil) and increased from Dec. 2022 ($381 Mil) to Dec. 2023 ($432 Mil).

Sandoz Group AG Construction In Progress Historical Data

The historical data trend for Sandoz Group AG's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG Construction In Progress Chart

Sandoz Group AG Annual Data

Trend

Dec22

Dec23

Construction In Progress

381.00

432.00

Sandoz Group AG Quarterly Data
	Dec22	Dec23
Construction In Progress	381.00	432.00

Sandoz Group AG Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Sandoz Group AG (Sandoz Group AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (OTCPK:SDZNY) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

SDZXF:USA SDZz:UK D8Y0:Germany SDZ:Switzerland

Address

Forum 1, Novartis Campus, Basel, CHE, CH-4056

Website

https://www.sandoz.com

Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as U.S.'s first biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in pipeline.

Sandoz Group AG (Sandoz Group AG) Headlines

From GuruFocus

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research • 02-14-2024

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research • 02-14-2024